Carmen Tur1, Mar Tintoré, Cristina Aguilera. Show Affiliations » 1. Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat), Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital Vall d'Hebron, Barcelona, España. ctur@cem-cat.org
Abstract
Entities: Disease
Mesh： See more » Abnormalities, Drug-InducedAbortion, Spontaneous/chemically inducedAntibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/therapeutic useFemaleFingolimod HydrochlorideGlatiramer AcetateHumansImmunologic Factors/adverse effectsImmunologic Factors/therapeutic useImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useInfant, NewbornInterferon-beta/adverse effectsInterferon-beta/therapeutic useMultiple Sclerosis/drug therapyNatalizumabPeptides/adverse effectsPeptides/therapeutic usePregnancyPregnancy Complications/drug therapyPrenatal Exposure Delayed Effects/chemically inducedPropylene Glycols/adverse effectsPropylene Glycols/therapeutic useSphingosine/adverse effectsSphingosine/analogs & derivativesSphingosine/therapeutic useStillbirth
Substances： See more » Antibodies, Monoclonal, HumanizedImmunologic FactorsImmunosuppressive AgentsNatalizumabPeptidesPropylene GlycolsGlatiramer AcetateInterferon-betaFingolimod HydrochlorideSphingosine
Year: 2012 PMID： 22743277 DOI： 10.1016/j.medcli.2012.04.021
Source DB: PubMed Journal: Med Clin (Barc) ISSN： 0025-7753 Impact factor: 1.725